Tag: Regenerative Medicine

FDA Grants RMAT Designation For Mesoblast’s Cell Therapy in Heart Failure Patients With LVADs

Coronary/Structural Heart Regulatory by 0 comments

NEW YORK and MELBOURNE, Australia, Dec. 21, 2017 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that the United States Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation for its novel mesenchymal precursor cell (MPC) therapy in the treatment of heart failure patients with left ventricular […]

Continue Reading →

Aziyo Continues Building New Breed of Regenerative Medicine Company

Coronary/Structural Heart Rhythm by 0 comments

SILVER SPRING, Md.–(BUSINESS WIRE)–Aziyo Biologics, Inc. a fully integrated regenerative medicine company, today announced it has completed an asset purchase agreement with CorMatrix� Cardiovascular, Inc. for the purchase of all CorMatrix  commercial assets and related intellectual property. With the acquisition, Aziyo will: Add 5 commercially marketed products Double topline revenue Add […]

Continue Reading →